FUP Stock Chart & Stats
€10.20
-€0.35(-3.59%)
At close: 4:00 PM EST
€10.20
-€0.35(-3.59%)
Day’s Range― - ―
52-Week Range€7.95 - €13.60
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€266.48M
Enterprise Value€78.17K
Total Cash (Recent Filing)€10.89B
Total Debt (Recent Filing)€29.62B
Price to Earnings (P/E)19.0
Beta0.37
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)98.82
Shares Outstanding26,541,100
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.24
Price to Book (P/B)0.80
Price to Sales (P/S)0.73
P/FCF Ratio9.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.58
Revenue Forecast (FY)€341.84M
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthSustained top-line growth signals expanding product adoption in Fuji Pharma's core women's health franchise and licensed portfolio. Durable revenue expansion improves ability to fund R&D and commercialization, supports scale advantages in manufacturing and distribution over the next 2-6 months.
Improving Free Cash FlowImproved free cash flow provides lasting financial flexibility to fund capex, service debt, and support partnerships or licensing. Over a medium horizon this reduces refinancing risk and enables reinvestment in pipeline and commercialization even if earnings remain volatile.
Balanced Capital Structure And Stable ROEA stable equity ratio combined with steady ROE indicates a balanced capital structure and consistent profitability. This durability supports resilience to shocks, preserves borrowing capacity, and underpins long-term investment in R&D and product launches without immediate dilution.
Bears Say
Rising LeverageIncreasing debt levels raise financial risk and interest burden, constraining strategic flexibility for M&A, product launches, or higher R&D spending. If leverage continues rising, it could pressure credit metrics and elevate refinancing or covenant risks over the medium term.
Margin Volatility And Recent DeclinesEroding and volatile EBIT and net margins reduce sustainable profitability and free cash generation. For a specialty pharma reliant on branded and licensed products, margin swings reflect pricing, cost, or mix pressures that complicate forecasting and limit durable earnings growth.
Weak Operating Cash Conversion Vs EarningsIf operating cash lags reported earnings, earnings quality and working capital can be concerns. Persistent weak cash conversion limits internal funding for commercialization and debt service even when net income is positive, raising medium-term liquidity risk if trends persist.
Fuji Pharma Co., Ltd. News
FUP FAQ
What was Fuji Pharma Co., Ltd.’s price range in the past 12 months?
Fuji Pharma Co., Ltd. lowest stock price was €7.95 and its highest was €13.60 in the past 12 months.
What is Fuji Pharma Co., Ltd.’s market cap?
Fuji Pharma Co., Ltd.’s market cap is €266.48M.
When is Fuji Pharma Co., Ltd.’s upcoming earnings report date?
Fuji Pharma Co., Ltd.’s upcoming earnings report date is Aug 06, 2026 which is in 12 days.
How were Fuji Pharma Co., Ltd.’s earnings last quarter?
Fuji Pharma Co., Ltd. released its earnings results on May 12, 2026. The company reported €0.083 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Fuji Pharma Co., Ltd. overvalued?
According to Wall Street analysts Fuji Pharma Co., Ltd.’s price is currently Overvalued.
Does Fuji Pharma Co., Ltd. pay dividends?
Fuji Pharma Co., Ltd. does not currently pay dividends.
What is Fuji Pharma Co., Ltd.’s EPS estimate?
Fuji Pharma Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Fuji Pharma Co., Ltd. have?
Fuji Pharma Co., Ltd. has 26,541,100 shares outstanding.
What happened to Fuji Pharma Co., Ltd.’s price movement after its last earnings report?
Fuji Pharma Co., Ltd. reported an EPS of €0.083 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Fuji Pharma Co., Ltd.?
Currently, no hedge funds are holding shares in DE:FUP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Fuji Pharma Co., Ltd.
Fuji Pharma Co., Ltd. is a pharmaceutical company that operates globally, focusing on the complete spectrum of drug development, from initial research and discovery through manufacturing and commercialization. Its comprehensive product line includes various medical solutions such as injectable medications, oral therapeutics, topical treatments, and a range of diagnostic tools. Beyond its core pharmaceutical offerings, Fuji Pharma also specializes in women's healthcare products, advanced in vitro diagnostic technologies, and acute medical intervention solutions. The company further contributes by disseminating valuable pharmaceutical and general health information. Founded in 1965, Fuji Pharma Co., Ltd. has its corporate headquarters located in Tokyo, Japan.
Technical Analysis
Mochida Pharmaceutical Co., Ltd.
―
Fuso Pharmaceutical Industries,Ltd.
―
KYORIN Pharmaceutical Co.,Ltd.
―
Daito Pharmaceutical Co., Ltd.
―
ASKA Pharmaceutical Holdings Co., Ltd.
―